New tip sheet available for the Behavioral Health HEDIS measure: Follow-Up Care for Children Prescribed ADHD Medication (ADD)

Nov. 2022Important Notices
The ADD HEDIS® measure outlines the importance for members 6 to 12 years old who are newly prescribed a medication for ADHD to receive, at minimum, three appointments—an initial appointment with the prescriber and subsequent appointments with the treatment team, including behavioral health treatment providers—within 10 months of starting the new medication. The tip sheet defines the HEDIS measure and offers providers tips to ensure continuity of care for their patients who are prescribed medications for ADHD for the first time. Learn more about the ADD HEDIS measure.

HEDIS®
The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of NCQA.

Recent Announcements

Voluntary nationwide recall: Cyclobenzaprine (Unichem – August 2025)

Unichem Pharmaceuticals (USA), Inc. is recalling one lot, lot GMML24026A, of Cyclobenzaprine Hydrochloride Tablets USP 10 mg. Cyclobenzaprine is used for the relief of muscle spasms from certain conditions.
Sep. 2025Pharmacy Updates

Voluntary nationwide recall: Lactated Ringers and 0.9% Sodium Chloride (B. Braun-Aug)

B. Braun Medical, Inc. is recalling two lots of Lactated Ringers Injection USP 1000 mL and 0.9% Sodium Chloride Injection USP 1000 mL. These are intravenous (IV) fluids commonly used in the hospital to treat dehydration and other conditions.
Aug. 2025Pharmacy Updates

CME Webinar: Evaluating Antimicrobial Stewardship Techniques in the Outpatient Setting

Please join us for a live, CME-accredited webinar on Tuesday, Nov. 4, from noon to 1 p.m. that will share an overview of evaluating antimicrobial stewardship techniques in the outpatient setting.
Aug. 2025Education/Webinars